All In Biotech

Drug Trial Radar · NCT07180355

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

A Phase 1b First-in-Human, Open-Label, Dose-Finding Trial to Evaluate the Safety and Tolerability of SGT-212 Delivered Via Dual Intradentate Nucleus (IDN) and Intravenous (IV) Administration to Participants With Friedreich's Ataxia (FA)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 22, 2025

Primary completion

Mar 21, 2028

Study completion Feb 29, 2032

Sponsor

Lead sponsor
Solid Biosciences Inc.Industry
Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.

Conditions

  • Friedreich's Ataxia (FA)

Interventions

  • SGT-212Drug

    Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)Time frame: Month 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The University of California, Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • The Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.